iFIT Cluster of Excellence Newsletter Vol. X

Dear members,

First of all, we wish you a Happy New Year 2026!

With our Email Newsletter, we want to keep you up to date with all new information surrounding our “Image-Guided and Functionally Instructed Tumor Therapies” Cluster of Excellence. Vol. X includes news, publications and general information from the past three months and upcoming events. The next newsletter will be published on April 1, 2026.

If you have any comments or feedback feel free to get in touch with us: ifitoffice@med.uni-tuebingen.de

With best regards,

iFIT Office Team

News

iFIT News

Article with Florian Wimmers in Immunity

iFIT News

Online interview with Lisa Sevenich

iFIT News

5th Days of Intravital Microscopy 

iFIT News

Summer School “An Introduction to Drug Discovery”

iFIT News

Judith Feucht receives Life Sciences Bridge Award

iFIT News

iFIT members at BrazMedChem 2025

iFIT News

iFIT Visualization Award 2025

iFIT News

Thorsten Stafforst & Mathias Heikenwälder receives ERC Synergy Grant

iFIT News

iFIT Strategy Retreat 2025

iFIT News

iFIT Merry Science Event 2025

iFIT News

Jan Böttcher receives ERC Consolidator Grant

iFIT News

Season’s Greetings

Get to know...

New iFIT Member

Prof. Dr. Jan Böttcher

Upcoming Events

Lunch & Learn

iFIT Lunch & Learn Session with Saskia Biskup

21^st of January at 12:00pm
Lecture hall N1, Auf der Morgenstelle

Distinguished Lecture

iFIT Distinguished Lecture Session with Twan Lammers

11^th of February at 12:00pm
Lecture Hall Women's Clinic

Workshop

Excellence Workshop Mod. I with Paul Charlton 

3^rd of March at 09:00am

iFIT Seminar Room

Talk

iFIT session on Power Misconductance with Inka Montero

16^th of March at 12:00pm
Lecture Hall ENT Clinic

Workshop

Excellence Workshop Mod. II with Paul Charlton

24^th of March at 09:00am

iFIT Seminar Room

Selected Publications

CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency

Bucher, P., Brückner, N., Kortendieck, J. et al. CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency. Nat Cancer (2026). https://doi.org/10.1038/s43018-025-01099-7. IF: 28.5

MHCquant2 refines immunopeptidomics tumor antigen discovery

Scheid, J. et al. MHCquant2 refines immunopeptidomics tumor antigen discovery. Genome Biol., Sep 22;26(1):290 (2025). 10.1186/s13059-025-03763-8. IF: 9.4

Discovery of the First Highly Selective 1,4-dihydropyrido[3,4- b]pyrazin-3(2H)-one MKK4 Inhibitor

Katzengruber L. et al.  Discovery of the First Highly Selective 1,4-dihydropyrido[3,4- b]pyrazin-3(2H)-one MKK4 Inhibitor. Journal of Medicinal Chemistry. 24;68(14):14782-14805. (Jul 2025) 10.1021/acs.jmedchem.5c00919.  IF: 6.8

PET-based immunomapping of intratumoral CD4+ cells to monitor acquired resistance to checkpoint inhibitors

Pezzana S. et al.  PET-based immunomapping of intratumoral CD4+ cells to monitor acquired resistance to checkpoint inhibitors. Science advances, 27;11(26):eadw1924 (Jun 2025). https://pubmed.ncbi.nlm.nih.gov/40561008/  IF: 12.5

PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development

Lemke, S. et al. PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development. Journal for Immunotherapy of Cancer, 15;13(4):e011366. (Apr 2025) 10.1136/jitc-2024-011366 IF: 10.6

Exceptional tumor-free survival of a patient with metastatic intrahepatic cholangiocarcinoma after surgery and personalized peptide vaccination: revisiting a striking case 

Maia, Ana et al. Exceptional tumor-free survival of a patient with metastatic intrahepatic cholangiocarcinoma after surgery and personalized peptide vaccination: revisiting a striking case. Journal for Immunotherapy of Cancer, 9;13(10):e012107. (Oct 2025)https://doi.org/10.1136/jitc-2025-012107 IF: 6.0

Job Offers

Public Relations Manager Science Communication 50% (f/m/d)

University Hospital of Tuebingen - Communications Department, iFIT Cluster of Excellence

Postdoc in CAR therapies and immune cell engineering (f/m/d)

University Hospital of Tuebingen - University Hospital for Paediatric and Adolescent Medicine

PhD student in CAR immune cell therapies (f/m/d)

University Hospital of Tuebingen - University Hospital for Paediatric and Adolescent Medicine

Medical/Biological Technical Assistant (f/m/d)

University Hospital of Tuebingen - University Hospital for Paediatric and Adolescent Medicine

Follow us on social media

Legal Notice

Cluster of Excellence

“Image-Guided and Functionally Instructed Tumor Therapies” (iFIT)
Röntgenweg 11
72076  Tübingen, Germany

Contact:

Public Relations
Steven Pohl

Mail: steven.patrick.pohl@med.uni-tuebingen.de

Click here to unsubscribe